Invokana Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Canagliflozin

Indications/Uses

Adjunct to diet & exercise & standard care therapy to improve glycemic control in adults w/ type 2 DM, reduce risk of major adverse CV events (CV death, nonfatal MI & stroke) in adults w/ type 2 DM & established CVD who have inadequate glycemic control & of ESRD, serum creatinine doubling, CV death & hospitalization for heart failure in adult patients w/ type 2 DM & diabetic nephropathy w/ albuminuria >300 mg daily.

Dosage/Direction for Use

Adult ≥18 yr 100 mg or 300 mg once daily. Patient on loop diurectics & elderly ≥75 yr Initially 100 mg once daily. Patient w/ eGFR ≥60 mL/min/1.73 m² 100 mg once daily. May be increased to 300 mg once daily for additional glycemic control, 30 to <60 mL/min/1.73 m² 100 mg once daily. Patient w/ albuminuria >300 mg daily Reduce risk of ESKD, serum creatinine doubling, CV death & hospitalization for heart failure May continue 100 mg once daily.

Administration

Should be taken on an empty stomach: Swallow whole. Preferably taken before the 1st meal of the day.

Contraindications

Hypersensitivity. Patients on dialysis.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BK02 - canagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.

Regulatory Classification

POM

Presentation/Packing

Form

Invokana FC tab 100 mg

Packing/Price

1's

Form

Invokana FC tab 300 mg

Packing/Price

1's

Invokana

canagliflozin

Manufacturer:

Janssen-Cilag